Acquired EGFR-resistant mutations in non–small cell lung cancer (NSCLC).

Luis E. Raez(Florida International University), Misako Nagasaka(University of California, Irvine), Hirva Mamdani(Wayne State University), Chadi Nabhan(University of Chicago), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Hina Khan(Albert Einstein College of Medicine), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Mark A. Socinski(Florida Hospital Cancer Institute), Carlos Carracedo Uribe(Memorial Healthcare System), Antoinette J. Wozniak(Wayne State University), Hossein Borghaei(Fox Chase Cancer Center)
Journal of Clinical Oncology
June 1, 2022
10.1200/jco.2022.40.16_suppl.9113
Cited by 4

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k